Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • News

A Look Into Healthcare Sector Value Stocks

By Benzinga Insights
December 25, 10:43 AM
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the…

BNTX

Read More
4 minute read
  • Management
  • News

Viatris Announces The Appointment Of Theodora “Doretta” Mistras As Chief Financial Officer, Effective March 1, 2024, And Philippe Martin As Chief R&D Officer With Immediate Effect

By Benzinga Newsdesk
December 16, 7:31 PM
Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024PITTSBURGH, Dec. 15, 2023

VTRS

Read More
1 minute read
  • News

5 Value Stocks To Watch In The Healthcare Sector

By Benzinga Insights
November 13, 10:44 AM
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are…

ADIL

Read More
1 minute read
  • Earnings

Recap: Viatris Q3 Earnings

By Benzinga Insights
November 7, 5:45 PM
Viatris (NASDAQ:VTRS) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:39 PM. Here’s what investors…

VTRS

Read More
25 minute read
  • Earnings

Earnings Scheduled For November 7, 2023

By Benzinga Insights
November 7, 7:34 AM
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

ABUS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Obesity Drug Wegovy’s Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost

By Vandana Singh
October 3, 12:17 PM
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy. 

LVMHF

Read More
5 minute read
  • General
  • Markets
  • News
  • Small Cap
  • Top Stories

‘Airbnb Has Foundational Cracks’, Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft’s Nadella Criticizes Google’s Exclusive Content Deals: Today’s Top Stories

By Vandana Singh
October 3, 10:11 AM
Benzinga

AAPL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris – Emerges As Winner

By Vandana Singh
October 3, 8:32 AM
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, 

NVO

Read More
2 minute read
  • Asset Sales
  • Equities
  • Large Cap
  • M&A
  • Markets
  • News

Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women’s Healthcare Business & More

By Lekha Gupta
October 2, 7:50 AM
Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by 

VTRS

Read More
1 minute read
  • News

Viatris To Divest OTC, Women’s Healthcare, And API Businesses In Strategic Move, For Up To $6.94B Of Total Gross Proceeds

By Benzinga Newsdesk
October 2, 3:07 AM
Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously Communicated

VTRS

Posts pagination

Previous 1 2 3 … 7 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service